Cargando…

Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia

OBJECTIVE: Sacubitril/valsartan is a relatively new medication that is more effective than the usual enalapril for heart failure patients with reduced ejection fraction. Therefore, this study aims to determine the cost-effectiveness of sacubitril/valsartan compared to enalapril in Indonesia’s health...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zakiyah, Neily, Sinuraya, Rano K, Kusuma, Arif S W, Suwantika, Auliya A, Lestari, Keri
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502020/ https://www.ncbi.nlm.nih.gov/pubmed/34675566 http://dx.doi.org/10.2147/CEOR.S322740

Ejemplares similares

Comparison of Sacubitril/Valsartan Versus Enalapril in the Management of Heart Failure
por: Bano, Shehar, et al.
Publicado: (2021)

Impact of Switch Options on the Economics of Pneumococcal Conjugate Vaccine (PCV) Introduction in Indonesia
por: Suwantika, Auliya A., et al.
Publicado: (2020)

Parents’ Knowledge, Attitude, and Practice on Childhood Vaccination During the COVID-19 Pandemic in Indonesia
por: Sinuraya, Rano K, et al.
Publicado: (2022)

Cost-Effectiveness of Contraceptive Use in Indonesia after the Implementation of the National Health Insurance System
por: Suwantika, Auliya A., et al.
Publicado: (2021)

Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand
por: Krittayaphong, Rungroj, et al.
Publicado: (2021)

Cost-Effectiveness of Sacubitril/Valsartan Compared with Enalapril in Patients with Heart Failure with Reduced Ejection Fraction: A Systematic Review
por: Rezapour, Aziz, et al.
Publicado: (2022)

Assessment of childhood immunization services at private healthcare facilities in Indonesia: a case study in a highly-populated city
por: Suwantika, Auliya A., et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Spending on Research and Development to Address the Needs for Innovative Therapeutic Products in Indonesia
por: Suwantika, Auliya A, et al.
Publicado: (2020)

Sacubitril–valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis
por: Hu, Tianyang, et al.
Publicado: (2023)

Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China
por: Wu, Yue, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Type 2 Diabetes Mellitus (T2DM) Treatment in Patients with Complications of Kidney and Peripheral Vascular Diseases in Indonesia
por: Priyadi, Akhmad, et al.
Publicado: (2021)

Cost-Effectiveness and Budget Impact Analyses of Pneumococcal Vaccination in Indonesia
por: Suwantika, Auliya A., et al.
Publicado: (2021)

Cost-Effectiveness of Dengue Vaccination in Indonesia: Considering Integrated Programs with Wolbachia-Infected Mosquitos and Health Education
por: Suwantika, Auliya A., et al.
Publicado: (2020)

The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction
por: Zhao, Ying, et al.
Publicado: (2022)

Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
por: Morrow, David A, et al.
Publicado: (2019)

Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Chemoradiation and Radiotherapy Treatment for Stage IIB and IIIB Cervical Cancer Patients
por: Puspitasari, Irma M, et al.
Publicado: (2021)

Cost-Effectiveness of Ferrous Fumarate–Folic Acid and Ferrous Gluconate–Multivitamins in a High Prevalence Area of Iron Deficiency Anemia in Indonesia
por: Rakanita, Yasinta, et al.
Publicado: (2021)

Safety and efficacy of ARNI (valsartan/sacubitril) vs ACEI (enalapril) in acute heart failure – A prospective observational study
por: Bhat, Tahir Saleem, et al.
Publicado: (2022)

Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran
por: Ravangard, Ramin, et al.
Publicado: (2023)

Hospitalization and Mortality in Patients With Heart Failure Treated With Sacubitril/Valsartan vs. Enalapril: A Real-World, Population-Based Study
por: Pathadka, Swathi, et al.
Publicado: (2021)

Use and Out‐of‐Pocket Cost of Sacubitril‐Valsartan in Patients With Heart Failure
por: Shore, Supriya, et al.
Publicado: (2022)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2016)

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial
por: Vardeny, Orly, et al.
Publicado: (2019)

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
por: McMurray, John J V, et al.
Publicado: (2018)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
por: Bocchi, Edimar Alcides, et al.
Publicado: (2018)

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study
por: Jain, Anil Ranjeetmal, et al.
Publicado: (2020)

Valsartan/Sacubitril in heart failure and hypotension: how, when and why
por: Scardovi, Angela Beatrice, et al.
Publicado: (2019)

Sacubitril/valsartan in heart failure and end‐stage renal insufficiency
por: Heyse, Alex, et al.
Publicado: (2019)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
por: Carballo, David, et al.
Publicado: (2020)

Renal protective effect of sacubitril/valsartan in patients with heart failure
por: Hsieh, Hui-Ling, et al.
Publicado: (2021)

Renal protection in chronic heart failure: focus on sacubitril/valsartan
por: Pontremoli, Roberto, et al.
Publicado: (2021)

The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
por: Xu, Yu, et al.
Publicado: (2023)

Discussing Out‐of‐Pocket Costs With Patients: Shared Decision Making for Sacubitril‐Valsartan in Heart Failure
por: Smith, Graham H., et al.
Publicado: (2018)

Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives
por: Yandrapalli, Srikanth, et al.
Publicado: (2017)

Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction
por: Dewan, Pooja, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_05q1qsrf88tl02k7k7ar6til7i